Adverse effects described in the medical literature as of 2017 included nausea, flushing, headache, injection-site pain and itchiness, and upper respiratory tract infections.<ref name=Gelman2017rev>{{cite journal|last1=Gelman|first1=F|last2=Atrio|first2=J|title=Flibanserin for hypoactive sexual desire disorder: place in therapy.|journal=Therapeutic advances in chronic disease|date=January 2017|volume=8|issue=1|pages=16-25|pmid=28203348|pmc=5298357}}</ref><ref name=Belkin2015rev/>
